The FDA’s approval of Wegovy for reducing cardiovascular disease risk in Medicare beneficiaries with obesity has the potential to significantly impact healthcare access and costs. An estimated 3.6 million Medicare beneficiaries could gain access to the drug, representing approximately 7% of all Medicare enrollees. The expansion could lead to a significant increase in Part D spending, with estimates suggesting an additional $3 billion if 10% of eligible beneficiaries use Wegovy. However, the coverage expansion could also reduce the cost of proposed legislation to lift the Medicare ban on obesity medication coverage.